A 28-year-old male patient with a history of resolved syphilis, HIV (viral load 30 copies, CD4 count 303), and active TB (first phase of treatment initiated on 9 August 2024, with expected completion by 13 October 2024) is currently undergoing the second phase of TB treatment (biconjugate therapy, initiated on 14 October 2024). This evidence concerns the gene CD4 and syphilis.